Skip to main content

Ventyx Biosciences, Inc.

VTYXDelisted Mar 4, 2026
Industry
Pharmaceutical Preparations
SEC CIK
0001851194

Ventyx Biosciences, Inc. was delisted on Mar 4, 2026; its insiders filed their last Form 4 on Mar 4, 2026; 139 institutions reported holding it in 13F filings for Q4 2025, worth $471.6M in total; no superinvestor held it.

Key figures

Market cap
–
Not available
Insider buys
0
Open market, last 90 days
Insider sells
0
Open market, last 90 days
13F holders
139
Q4 2025, +29 vs. previous quarter
13F value
$471.6M
Reported value at the end of Q4 2025
Superinvestors holding
0
At the end of Q4 2025

From SEC filings, in USD.

Revenue, FY2024
–
No comparable prior period
Net income, FY2024
-$135.1M
No comparable prior period
Free cash flow, FY2024
-$131.1M
No comparable prior period
Revenue, Q3 FY2025
–
No comparable prior period

Short interest

See short data

From FINRA, settlement date Feb 27, 2026.

Short interest
4.86M
Shares sold short
Change
+376.8K
+8.4% vs. previous
Days to cover
1.24
At average daily volume

Superinvestors holding VTYX, Q4 2025

Go to the superinvestors tab

No superinvestor reported holding VTYX at the end of Q4 2025.

Latest insider trades

See all insider trades

Open-market purchases and sales by Ventyx Biosciences, Inc. insiders from Form 4, newest first.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Dec 19, 2025 (view filing)Dec 181 dayMohan RajuCEO AND PRESIDENTSSale−47.3K$7.72−$365.5K−2.0%2.37M after
Dec 19, 2025 (view filing)Dec 181 dayNuss JohnCHIEF SCIENTIFIC OFFICERSSale−12.7K$7.72−$97.9K−2.5%489.5K after
Apr 3, 2025 (view filing)Apr 21 dayNuss JohnCHIEF SCIENTIFIC OFFICERSSale−1.89K$1.07−$2.02K−0.4%467.2K after
Dec 30, 2024 (view filing)Dec 273 daysNuss JohnCHIEF SCIENTIFIC OFFICERSSale−21.1K$2.36−$49.8K−4.3%464.6K after
Dec 26, 2024 (view filing)Dec 233 daysGujrathi SheilaDirectorPPurchase+130.0K$2.31+$300.3KNew position130.0K after
Dec 19, 2024 (view filing)Dec 19Same dayNuss JohnCHIEF SCIENTIFIC OFFICERSSale−13.2K$2.26−$29.7K−2.6%485.7K after
Nov 25, 2024 (view filing)Nov 22-253 daysMohan RajuCEO AND PRESIDENTPPurchase+500.0K$1.92+$962.1K+29.9%2.18M after2 lots
Apr 3, 2024 (view filing)Apr 21 dayKrueger Christopher WCHIEF BUSINESS OFFICERSSale−1.65K$5.40−$8.92K−0.6%285.0K after
Apr 3, 2024 (view filing)Apr 21 dayNuss JohnCHIEF SCIENTIFIC OFFICERSSale−1.65K$5.40−$8.92K−0.6%265.0K after
Apr 3, 2024 (view filing)Apr 21 dayMohan RajuCEO AND PRESIDENTSSale−4.31K$5.40−$23.3K−0.3%1.58M after

Top 10 13F holders, Q4 2025

See all 139 holders

The largest institutional positions in Ventyx Biosciences, Inc. at the end of Q4 2025; share changes are against Q3 2025.

Institutions holding VTYX in Q4 2025
InstitutionSharesValue% of portfolioChange in sharesAction
Affinity Asset Advisors, LLC6,484,558$58.6M4.21%+2,560,143+65.2%Added
Morgan Stanley4,292,951$38.8M0.00%+4,049,194+1,661.2%Added
Vanguard Group Inc3,943,566$35.6M0.00%+173,569+4.6%Added
BlackRock, Inc.3,142,440$28.4M0.00%+1,959,200+165.6%Added
Tang Capital Management LLC2,814,000$25.4M1.26%−286,000−9.2%Reduced
Baker Bros. Advisors LP2,349,280$21.2M0.12%+1,326,150+129.6%Added
Braidwell LP1,920,255$17.3M0.55%+1,920,255New
D. E. Shaw & Co., Inc.1,665,474$15.0M0.01%+1,142,786+218.6%Added
MPM Oncology Impact Management LP1,639,061$14.8M1.69%+1,639,061New
Citadel Advisors LLC1,563,611$14.1M0.01%−316,378−16.8%Reduced

Holders of 5% or more of VTYX

See all 4 holders and filings

Holders whose latest Schedule 13D or 13G filing reports 5% or more of Ventyx Biosciences, Inc..

Largest holders of VTYX from 13D and 13G filings
HolderLatest formStakeChangeFirst filedLatest filingFiling
NSV Investments I, L.P.13D/A7.60%5.43M shares–Oct 29, 202113 filingsMar 12, 2025SEC
Mohan Raju13D/A6.00%4.39M shares0.00 ppfrom 6.00%Nov 26, 20252 filingsJan 9, 2026SEC
NSV Partners III LP13D/A5.70%4.09M shares–Apr 1, 20251 filingApr 1, 2025SEC
Vanguard Group Inc13G5.28%3.77M shares–Feb 13, 20244 filingsOct 31, 2025SEC